# AMT-116 in Patients with Solid Tumors

> **NCT06782334** · PHASE1,PHASE2 · RECRUITING · sponsor: **Multitude Therapeutics Inc.** · enrollment: 144 (estimated)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** AMT-116

## Key facts

- **NCT ID:** NCT06782334
- **Lead sponsor:** Multitude Therapeutics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-05-07
- **Primary completion:** 2026-06-30
- **Final completion:** 2026-12-30
- **Target enrollment:** 144 (ESTIMATED)
- **Last updated:** 2025-01-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06782334

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06782334, "AMT-116 in Patients with Solid Tumors". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06782334. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*